

# Christina Sorbe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/387329/publications.pdf>

Version: 2024-02-01

33  
papers

2,244  
citations

471477

17  
h-index

395678

33  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2009  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. <i>British Journal of Dermatology</i> , 2022, 187, 588-589.  | 1.5 | 3         |
| 2  | Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2021, 184, 548-550.   | 1.5 | 4         |
| 3  | A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 701-711. | 2.4 | 13        |
| 4  | Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004-2017. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1536-1542.   | 2.4 | 18        |
| 5  | A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2020, 182, 869-879.       | 1.5 | 31        |
| 6  | Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019, 181, 358-365.   | 1.5 | 42        |
| 7  | Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 1100-1105.  | 2.6 | 27        |
| 8  | Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatments: results from the randomized controlled PRIME trial. <i>British Journal of Dermatology</i> , 2017, 177, 1024-1032.   | 1.5 | 48        |
| 9  | Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm <sup>®</sup> - and placebo-controlled trial (BRIDGE). <i>British Journal of Dermatology</i> , 2017, 176, 615-623.   | 1.5 | 111       |
| 10 | European S3 Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – <sup>EDF</sup> in cooperation with <sup>EADV</sup> and <sup>IPC</sup> . <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.                                      | 2.4 | 353       |
| 11 | German S3-guidelines on the treatment of psoriasis vulgaris (short version). <i>Archives of Dermatological Research</i> , 2012, 304, 87-113.   | 1.9 | 96        |
| 12 | European S3 Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.  | 2.4 | 683       |
| 13 | Treatment targeted to cell surface epitopes. <i>Clinical and Experimental Dermatology</i> , 2002, 27, 591-596.   | 1.3 | 25        |
| 14 | Advances in systemic therapy for psoriasis. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 362-367.  | 1.3 | 33        |
| 15 | Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells. <i>Experimental Dermatology</i> , 2001, 10, 238-245.  | 2.9 | 28        |
| 16 | Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. <i>British Journal of Dermatology</i> , 1999, 141, 424-429.  | 1.5 | 193       |
| 17 | Macrolide immunosuppressants. <i>European Journal of Dermatology</i> , 1999, 9, 346-51.  | 0.6 | 18        |
| 18 | Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. <i>British Journal of Dermatology</i> , 1998, 138, 456-460.   | 1.5 | 214       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. <i>British Journal of Dermatology</i> , 1998, 139, 992-996.  | 1.5 | 103       |
| 20 | Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. <i>British Journal of Dermatology</i> , 1997, 136, 542-7.  | 1.5 | 4         |
| 21 | A method for the determination of leukocyte migration for large sample numbers by automated densitometric quantification. <i>Journal of Proteomics</i> , 1995, 30, 49-58.   | 2.4 | 9         |
| 22 | Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 470-475.                | 1.2 | 69        |
| 23 | Infiltrating Neutrophils Differ from Circulating Neutrophils when Stimulated with C5a, NAP-I/IL-8, LTB4 and FMLP. <i>Scandinavian Journal of Immunology</i> , 1992, 35, 71-78.  | 2.7 | 6         |
| 24 | Inhibition of human monocyte functions by anthralin. <i>British Journal of Dermatology</i> , 1992, 127, 382-386.  | 1.5 | 17        |
| 25 | The enigma of cyclosporin A treatment for psoriasis: systemic efficacy versus topical non-responsiveness. A review. <i>Acta Dermato-Venereologica</i> , 1992, 72, 321-6.  | 1.3 | 3         |
| 26 | Neutrophil-activating peptide 1/interleukin 8 mRNA expression and protein secretion by human monocytes: Effect of cyclosporin A. <i>Cytokine</i> , 1991, 3, 322-326.  | 3.2 | 13        |
| 27 | Selective Inactivation of Human Neutrophil Elastase by Synthetic Tannin. <i>Journal of Investigative Dermatology</i> , 1991, 97, 529-533.   | 0.7 | 16        |
| 28 | Recombinant Human Tumour Necrosis Factor beta (Lymphotoxin) Lacks Chemotactic Activity for Human Peripheral Blood Neutrophils, Monocytes, and T Cells. <i>Scandinavian Journal of Immunology</i> , 1989, 30, 373-377.   | 2.7 | 3         |
| 29 | Modulation of Human Monocyte Functions during Acute Bacterial Infection. <i>Scandinavian Journal of Immunology</i> , 1988, 28, 139-146.   | 2.7 | 7         |
| 30 | Atopic dermatitis: Influence of bacterial infections on human monocyte and neutrophil granulocyte functional activities. <i>Journal of Allergy and Clinical Immunology</i> , 1988, 82, 1027-1036.                       | 2.9 | 11        |
| 31 | Recombinant human tumor necrosis factor $\hat{\pm}$ lacks chemotactic activity for human peripheral blood neutrophils and monocytes. <i>Biochemical and Biophysical Research Communications</i> , 1988, 153, 1223-1228. | 2.1 | 37        |
| 32 | Effects of cyclosporine A treatment on psoriasis. I: Influence of low-dose cyclosporine on human monocyte function in vitro. <i>Transplantation Proceedings</i> , 1988, 20, 53-7.                                       | 0.6 | 2         |
| 33 | C5a-Specific Modulation of Phagocyte Functions in Patients with Localized Bacterial Infections. <i>Immunobiology</i> , 1987, 174, 460-472.  | 1.9 | 4         |